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Background: The functional importance of apolipoprotein A-I (apoA-I) nitration at tyrosine 166 (Tyr166) in vivo is
controversial.
Results:Nitrotyrosine 166-apoA-I accounts for 8% of apoA-I within human atheroma, is not HDL-associated, and is function-
ally impaired.
Conclusion:Buoyant density ultracentrifugation ofHDLcan lead to erroneous results, particularlywithmodified apoA-I forms.
Significance:Detection and quantification of nitrotyrosine 166-apoA-I may provide insights into a pathophysiological process
within the artery wall.
We reported previously that apolipoprotein A-I (apoA-I) is
oxidatively modified in the artery wall at tyrosine 166 (Tyr166),
serving as a preferred site for post-translational modification
through nitration. Recent studies, however, question the extent
and functional importance of apoA-I Tyr166 nitration based
upon studies of HDL-like particles recovered from atheroscle-
rotic lesions. We developed a monoclonal antibody (mAb
4G11.2) that recognizes, in both free and HDL-bound forms,
apoA-I harboring a 3-nitrotyrosine at position 166 apoA-I
(NO2-Tyr166-apoA-I) to investigate the presence, distribution,
and function of this modified apoA-I form in atherosclerotic
and normal artery wall.We also developed recombinant apoA-I
with site-specific 3-nitrotyrosine incorporation only at position
166 using an evolved orthogonal nitro-Tyr-aminoacyl-tRNA
synthetase/tRNACUA pair for functional studies. Studies with
mAb 4G11.2 showed that NO2-Tyr166-apoA-I was easily
detected in atherosclerotic human coronary arteries and
accounted for8%of total apoA-Iwithin the arterywall butwas
nearly undetectable (>100-fold less) in normal coronary arter-
ies. Buoyant density ultracentrifugation analyses showed that
NO2-Tyr166-apoA-I existed as a lipid-poor lipoprotein with
<3% recovered within the HDL-like fraction (d 1.063–1.21).
NO2-Tyr166-apoA-I in plasma showed a similar distribution.
Recovery of NO2-Tyr166-apoA-I using immobilized mAb
4G11.2 showed an apoA-I form with 88.1  8.5% reduction in
lecithin-cholesterol acyltransferase activity, a finding corrobo-
rated using a recombinant apoA-I specifically designed to
include the unnatural amino acid exclusively at position 166.
Thus, site-specific nitration of apoA-I at Tyr166 is an abundant
modificationwithin the arterywall that results in selective func-
tional impairments. Plasma levels of this modified apoA-I form
may provide insights into a pathophysiological process within
the diseased artery wall.
Post-translational modification (PTM)4 of proteins through
multiple distinct oxidative processes is a common occurrence
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at sites of inflammation and cardiovascular disease (1–11).
Inflammation and oxidative stress arewidely touted as playing a
role in the pathogenesis of cardiovascular disease; however,
studies aimed at understanding the functional consequences of
modifications of proteins through these processes have proven
difficult. Onemajor reason for this is that exposure of a protein
to an oxidative source resulting in PTM of the targeted amino
acid typically also oxidizes many other susceptible amino acids,
making conclusions of the functional impact of PTM of a spe-
cific residue difficult. To circumvent this problem,we andother
investigators have used oxidative modification in combination
with site-specific mutagenesis studies to provide data in sup-
port of the involvement of specific residues and types of PTMs
with alterations in protein function (12, 13). Although instruc-
tive, this course of action is not ideal for a number of reasons,
including the fact that mutagenesis of a targeted residue to a
non-oxidizable residuemayhave unknown effects on other bio-
logical interactions or functions of the protein that are not
immediately apparent. Additionally, the problems of oxidative
modification on other residues within the protein occurring
concurrently cannot be avoided and remain a limitation of this
approach.
Recent advances in the use of evolved orthogonal amino acid
synthetases and their paired tRNACUA has enabled the devel-
opment of technology allowing for site-specific incorporation
of non-physiologic amino acids into recombinant proteins
(14–16). This capability has the potential to allow one to study
the functional consequences of individual PTM to residues that
have previously been implicated as playing a functional role
based on their detection by proteomics studies in the material
recovered from diseased tissue (16, 17).
We demonstrated previously that apoA-I recovered from
human atherosclerotic lesions is heavily oxidized (7–9, 18), a
finding that others have replicated (6, 19, 20). Proteomic iden-
tification of oxidatively modified sites within apoA-I isolated
from atherosclerotic lesion by immunoprecipitation with
apoA-I-specific antibodies identified a number of preferred
residues for MPO- and NO-derived oxidant PTMs (8, 9). In
addition to apoA-I tyrosine 192, for which mutagenesis studies
by our group failed to demonstrate changes in biological activ-
ity, tyrosine 166 of apoA-I was reported as being of particular
interest because this site was also shown to be within a region
we identified as a “solar flare,” a solvent-exposed region on nas-
cent HDL that we predicted interacts with lecithin-cholesterol
acyltransferase (LCAT) (12). Based upon mutagenesis of this
residue to phenylalanine and functional analyses, we predicted
that nitration of the endogenous tyrosine at this sitemay impair
LCAT activity (12).
Other investigators have studied oxidative PTMs on apoA-I
present in atherosclerotic lesions not by immunoprecipitating
total apoA-I but rather exclusively by “floating” HDL-like par-
ticles (d1.063–1.21g/ml)usingbuoyantdensityultracentrifu-
gation (6, 7, 19, 21, 22). Proteomics analysis of buoyant density-
isolatedHDL-like fractions confirms tyrosine 192 as a preferred
oxidation site on apoA-I through MPO-catalyzed chlorination
in both human plasma- and lesion-derived apoA-I (21, 22). The
major site of nitration in plasma-derived apoA-I in HDL was
also reported to be tyrosine 192, whereas tyrosine 18 was found
to be a major site reported from lesion “HDL-like” particle-
localized apoA-I (22). In these latter studies where apoA-I was
recovered from plasma or lesions by floating HDL, little nitra-
tion at tyrosine 166 was observed, and the involvement of this
site in modification was suggested to have little biological rel-
evance (22). Thus, there exists a discrepancy of the impor-
tance of modification within apoA-I with regard to the abun-
dance and functional significance of tyrosine 166 oxidative
modification.
The quantitative significance and functional consequences
of apoA-I nitration at tyrosine 166 are of potential clinical and
therapeutic importance. ApoA-I-targeted therapies such as
direct delivery of the protein intravenously for promotion of
atherosclerotic plaque regression is currently under investiga-
tion. A better understanding of the true sites of oxidative mod-
ification of apoA-I and their functional significancemay thus be
relevant to the generation of oxidation-resistant mutant forms
of apoA-I with the potential to provide enhanced cardioprotec-
tive action compared with that observed with the native form
(13). A better understanding would also be useful for develop-
ment of potential diagnostic tools to monitor processes ongo-
ing within the diseased artery wall or with which to potentially
titrate response to therapies.
Hereinwe show, through use of a novelmonoclonal antibody
(mAb) that specifically recognizes apoA-I harboring a 3-nitro-
tyrosine at position 166 (NO2-Tyr166-apoA-I), that this modi-
fied form of apoA-I is abundant within the artery wall in a lipid-
poor form rather than on an HDL particle. Furthermore, by
generating recombinant apoA-I that selectively incorporates a
lone 3-nitrotyrosine at 166 in apoA-I, we show that this PTM
rendered apoA-I severely impaired in stimulating LCAT activ-
ity as a nascent HDL particle but had no effect on cholesterol
efflux activity. Given the abundance of NO2-Tyr166-apoA-I
observed within arterial tissues, detection of NO2-Tyr166-
apoA-I within the circulation may thus serve as a means to
monitor a pathophysiologically relevant process occurring in
the artery wall during atherosclerosis. Moreover, the present
studies showed that methods used to examine apoA-I within
the artery wall are important for gauging the quantity and func-
tional significance of modified apoA-I forms in vivo.
EXPERIMENTAL PROCEDURES
Materials—D2O was purchased from Cambridge Isotopes,
Inc. (Andover, MA). Chelex-100 resin, fatty acid-free bovine
serum albumin (BSA), and crystalline catalase (from bovine liv-
er; thymol-free) were purchased from Roche Applied Science.
Human MPO was isolated and characterized as described (1).
[3H]Cholesterol was obtained from Amersham Biosciences.
The immunoglobulin class of the mouse mAb kit was obtained
from Invitrogen. Trypsin was from Promega (Madison, WI),
and the RAW264.7 cell line was from the American Type Cul-
ture Collection (Manassas, VA). Sodium phosphate, H2O2, and
NaOCl were purchased from Fisher. Peroxynitrite (ONOO)
was purchased from Cayman Chemicals (Ann Arbor, MI). All
rosine at position 166; rHDL, reconstituted HDL; Mj, Methanococcus jann-
aschii; LPD, lipoprotein-depleted; HDLc, HDL-cholesterol; oxTrp72-apoA-I,
2-oxindolyl alanine moiety at Trp72 of apoA-I.
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other materials were purchased from Sigma except where
indicated.
General Methods—Human apoA-I was purified from circu-
lating HDL obtained from healthy volunteer donors using
establishedmethods (12, 23). All donors gave written informed
consent, and the Institutional Review Board of the Cleveland
Clinic approved all study protocols. Mouse studies involving
monoclonal antibody generation were performed under proto-
cols approved by the Institutional Animal Care and Use Com-
mittee at the Cleveland Clinic. Lipoproteins, including HDL
and HDL-like particles (d  1.063–1.21) from plasma and tis-
sue homogenates, respectively, were isolated by sequential
buoyant density ultracentrifugation at low salt concentrations
using D2O/sucrose (24). Protein concentrations were deter-
mined by theMarkwell modified protein assay (25) with bovine
serum albumin as the standard. Cholesterol efflux and LCAT
activity assays were performed as described (23, 26, 27). Recon-
stitutedHDL (rHDL) was prepared from isolated apoA-I by the
cholate dialysis method (28) using a molar ratio of apoA-I:1-
palmitoyl-2-oleoylphosphatidylcholine:cholesterol of 1:100:10.
HDLparticleswere further purified by gel filtration chromatog-
raphy using a Sephacryl S300 column (GE Healthcare) on a
Bio-Rad Biologics DuoFlo FPLC. Reconstituted nascent HDL
particle preparationswere further characterized by native poly-
acrylamide gel electrophoresis (PAGE), and lipid composition
analyses were determined (23, 12).MPO (donor, hydrogen per-
oxide; myeloperoxidase, EC 1.11.2.2) was isolated (final A430/
A280 ratio of 0.6) as described (29). Enzyme concentration was
determined spectrophotometrically (430  170 mM1 cm1)
(30). H2O2 and OCl concentrations were each determined
spectrophotometrically (240 39.4 M1 cm1) (31) and 292
350 M1 cm1 (32), respectively) immediately prior to use.
ONOO was quantified spectrophotometrically prior to use
(302  1.36 mM1 cm1) (33). All buffers used were passed
through a Chelex-100 column and supplemented with 100 M
diethylenetriaminepentaacetic acid (DTPA) to remove any
trace levels of redox-active transitionmetals. All glassware used
was rinsed with 100 M DTPA, pH 7.4 and then Chelex-100-
treated distilled deionized H2O and then baked at 500 °C prior
to use. Sodium dodecyl sulfate (SDS)-PAGE was performed as
described by Laemmli (34).
Bacterial Cells—Escherichia coli TOP10 cells (Invitrogen)
were used for cloning purposes and for expression of His8-C3-
apoA-I (referred to as wild type (WT) apoA-I) as described
below. NO2-Tyr166-apoA-I protein was expressed in an E. coli
TOP10 strain harboring the evolved orthogonal Methanococ-
cus jannaschii (Mj) nitro-Tyr-tRNA synthetase/tRNACUA pair
that specifically incorporates 3-nitrotyrosine into amber
codons (16).
Plasmids—Plasmid (pUC57-apoA-I) was created by blunt
end cloning of an E. coli codon-optimized human apoA-I DNA
sequence encoding the mature apoA-I polypeptide, amino
acids 25–267 (amino acids preceded by an in-frame amino-
terminal His8-C3 protease site tag; gene synthesized by Gene-
script, Piscataway, NJ) into the EcoRV site of pUC57. TheHis8-
C3-apoA-I DNA fragment was excised with digestion by NcoI
and KpnI restriction enzymes, and the gene fragment was
cloned into arabinose-inducible pBAD/myc/His6 backbone
(Invitrogen) at those same restriction sites, eliminating the vec-
tor-encodedHis6 tag to create pBAD apoA-I-3C using T4DNA
ligase. TheY166Fmutant in apoA-I tyrosine at position 166was
constructed by site-directed mutagenesis changing the TAT
(Tyr) to TTT (Phe) using a QuikChangeTM II mutagenesis kit
(Stratagene, La Jolla, CA) to create pBAD apoA-I 166F. The
His8-C3-apoA-I allele expressing apoA-Iwith a nitrotyrosine to
be incorporated at position 166was constructed and denoted as
pBAD apoA-I-3C-166TAG. Briefly, the codon for the tyrosine
166 residue in the human apoA-I sequence was replaced by an
amber stop codon (TAG) by site-directed mutagenesis. Site-
directed mutagenesis was carried out using QuikChangeTM II
(Stratagene). After mutagenesis, clones were isolated and
sequenced to confirm the altered sequence. The amber codon is
suppressed by the orthogonal nitrotyrosine Mj-tRNACUA/Mj-
tRNA synthetase engineered to incorporate 3-nitrotyrosine
only at amber codons (pDULE 5B) (16). The modified protein
was expressed and purified as described below for recombinant
human apoA-I.
Protein Expression—Plasmids containing the apoA-I wild
type and apoA-I Tyr166 TAG stop codonwere transformed into
E. coli TOP10 cells and TOP10 cells harboring the evolved
orthogonal Mj-nitro-Tyr-tRNA synthetase/tRNACUA pair,
respectively, and grown under antibiotic selection (100 mg/ml
ampicillin and 15 g/ml tetracycline). Protein expression was
carried out using a modified M9 medium. M9 salts were sup-
plemented with 0.375% glycerol, 0.05% glucose, 1 mM MgSO4,
0.1 mM CaCl2, 0.03% casamino acids, 1 basal medium Eagle
vitamin solution (Sigma), and 0.05% arabinose. Additionally,
with NO2-Tyr166-apoA-I expressed proteins, 1 mM free 3-ni-
trotyrosinewas added.Overnight cultures ofE. coliwere grown
in 50ml of LB containing the appropriate antibiotics with shak-
ing at 37 °C until theA600 reached 0.8. These cultures were then
spun down and resuspended in 10 ml of the M9 supplemented
medium described above. The suspension (2 ml) was then
added to 500ml of theM9 supplementedmedium and grown at
37 °C with shaking to an A600 of 0.8–1. At this point, cells were
left shaking overnight at room temperature. Cells were then
spun down, and the pellets were frozen at80 °C until required
for purification as described (23).
After purification of proteins on nickel affinitymatrices, pro-
teins were extensively dialyzed in the buffer of choice prior to
use. Incorporation of 3-nitrotyrosine into the recombinant
apoA-Iwas detected by scanning spectrophotometrywithmax-
imal absorbance at 428 nm.The extent of 3-nitrotyrosine incor-
poration at the desired position (166) of apoA-I was also con-
firmed by proteomics analysis quantifying both wild-type and
3-nitrotyrosine-containing tryptic peptides (see below).
Tissue Collection—Surgical specimens of freshly isolated
human aortic tissuewere obtained as discardedmaterial both at
time of organ harvest from transplant donors and during valve/
aortic arch (“elephant trunk”) replacement surgery. Aortic tis-
sue was immediately rinsed in ice-cold normal saline until free
of visible blood, submerged in argon-sparged phosphate buffer
(65 mM sodium phosphate, pH 7.4) supplemented with 100 M
DTPA and 100 M butylated hydroxytoluene, and stored at
80 °C in threaded cap specimen containers in which head-
space was purged with argon prior to freezing. Butylated
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hydroxytoluene was omitted from buffer in specimens where
apoA-I was isolated for functional activity assays.
mAb Generation, Specificity, and Labeling—mAb 10G1.5
(anti-total apoA-I) was used for isolation and quantification of
total apoA-I. This mAb was recently developed and extensively
characterized in our laboratory and demonstrates equal recog-
nition of lipid-free and lipidated (in rHDL) apoA-I under native
conditions as well as following oxidation by exposure to multi-
ple different oxidation systems, including MPO/H2O2/Cl,
MPO/H2O2/NO2, and CuSO4 (oxidized as outlined below for
mAb 4G11.2). For quantitative Western blot analyses, mAb
10G1.5 was IRDye-labeled (Li-COR Biosciences, Lincoln, NE)
using a dye:protein ratio of 4:1, and proteins were visualized by
infrared imaging. Coupling of dye to the antibody was per-
formed according to the manufacturer’s instructions.
A monoclonal antibody specific for 3-nitrotyrosine within
apoA-I specifically at residue 166 (mAb 4G11.2) was prepared
and characterized as follows. Hybridoma cell lines were gener-
ated by immunizing apoA-I/mice with purified delipidated
human apoA-I isolated from HDL recovered from healthy
donors that had been nitrated in vitro in chloride-free phos-
phate buffer using the completeMPO/H2O2/NO2 system at an
apoA-I:H2O2mol:mol ratio of 1:5 (NO2-A1) using 19 nMMPO,
100 M DTPA, 40 M H2O2, and 1 mM NaNO2 as described
(12). Several positive clones were further subcloned and
screened until an mAb with the desired binding specificity for
nitrated apoA-I forms with appropriate site-specific recogni-
tion for an epitope containing NO2-Tyr at apoA-I position 166
(see below) was identified. The subclone, mAb 4G11.2, was
selected from among these by further screening for equal rec-
ognition of lipid-free and lipidated (in rHDL) nitrated apoA-I
under native conditions as well as following oxidation by only
nitrative oxidation systems but not exposure to multiple other
different systems, including MPO/H2O2/Cl and CuSO4 (oxi-
dized as outlined below).
The specificity of mAb 4G11.2 was tested using apoA-I or
rHDL either in native form or following incubation at 37 °C in
60mM sodium phosphate buffer, pH 7.4 withmultiple different
oxidation systems. The different MPO systems consisted of 19
nMMPO, 100MDTPA, 40MH2O2, and either 100mMNaCl,
1 mM KBr, or 1 mM NaNO2 as indicated. Horseradish peroxi-
dase (HRP; 19 nM) was used with 40 M H2O2. ApoA-I and
rHDLwere exposed toMPOorHRP for 90min at 37 °C, and the
reactionswere stop by addition of 2mMmethionine and 300 nM
catalase. All other oxidation reactions were carried out for 24 h
at 37 °C. Final concentrations of oxidants used were: H2O2, 40
M;ONOO, 40M;ONOO/HCO3 (40Meach); CuSO4, 10
M; CuSO4/H2O2, 10 and 40 M, respectively; FeCl3, 10 M;
and FeCl3/H2O2, 10 and 40 M, respectively. ApoA-I or rHDL
(prepared from apoA-I or various oxidized versions of apoA-I)
were coated at 0.5 g/ml into enzyme immunoassay plates and
probed with 10 ng/ml anti-nitrotyrosine apoA-I monoclonal
antibody 4G11.2 at room temperature for 1 h.
Epitope mapping of the recognition region for mAb 4G11.2
was performed by coating enzyme immunoassay plates with
peptides (10 M) of human apoA-I that contained a tyrosine
centrally located within the peptide or identical versions of the
peptides with 3-nitrotyrosine incorporated as follows: Tyr18
(DLATVYVDVLK), NO2-Tyr18 (DLATV[NO2-Y] VDVLK),
Tyr166 (THLAPYSDELR), NO2-Tyr166 (THLAP[NO2-Y]S-
DELR), Tyr192 (LAEYHAK), and NO2-Tyr192 (LAE[NO2-
Y]HAK). Peptides were synthesized by Ohio Peptide (Powell,
OH). For quantitative Western blot analyses, purified mAb
4G11.2 was IRDye-labeled (Li-COR Biosciences) by using a LI-
COR IRDye 680RD high molecular kit at a dye:protein ratio of
4:1 and visualized by infrared imaging. Couplingwas performed
according to the manufacturer’s instructions.
To produce sufficient levels of 4G11.2 for immunoaffinity
purification of apoA-I from arterial tissues, hybridoma clones
were injected into pristane-treated male BALB/c mice for asci-
tes tumor production. Ascites fluid was collected, and proteins
were precipitated with ammonium sulfate and then chromato-
graphed on a protein A/G column (Pierce) to purify mouse
monoclonal antibodies. Isotypes of the mAbs were determined
with the mouse mAb isotyping kit (catalogue number 26179,
Pierce Rapid Antibody Isotyping Strips plus  and -Mouse,
Thermo Scientific Pierce).
HumanApoA-I Quantification—Human apoA-I was quanti-
fied by an Food and Drug Administration-approved apoA-I
immunoassay using the Abbott ARCHITECT ci8200 Inte-
gratedAnalyzer System (Abbott Laboratories, Abbott Park, IL).
All other apoA-I was quantified by quantitative immunoblot
analysis using mAb 10G1.5 as the detecting antibody as deter-
mined against a standard curve of known amounts of purified
apoA-I standard. Immunoreactive bands were quantified using
Image Studio software (version 2; LI-COR Biosciences) or NIH
ImageJ (version 1.46).
Aortic TissueHomogenization—Atherosclerotic lesions from
human aortic tissues were obtained from subjects (n 20) with
an average age of 81  6 years. Normal human aortic tissues
were obtained at the time of organ harvest from transplant
donors (n 5)with an average age of 27 4 years. Frozen tissue
pieces (submerged in argon-sparged 65 mM sodium phosphate
buffer, pH 7.4 with headspace purged with argon within screw
cap containers) were thawed in an ice/water bath. Immediately
after thawing, ice-cold Ca2- and Mg2-free Chelex-100-
treated PBS that had been supplemented with 100 M DTPA,
pH 7.4 was used to rinse the tissue at least five times to remove
residual blood from the tissue. Residual fat was also removed
from the aorta segments. The aorta segmentswere immediately
placed into Petri dishes containing ice-cold PBS that had been
supplementedwith 100MDTPA, pH7.4. The adventitial layer
was dissected away, the aorta was liberally rinsed with ice-cold
PBS supplemented with 100 MDTPA at least three additional
times, and then the wet weight of the aorta was determined.
Aortic tissue was then cut into small pieces in preparation for
mincing. Prior to mincing the tissue, a protease inhibitor mix-
ture (catalogue number P8340, Sigma-Aldrich)was added. This
mixture was also included in all subsequent solutions used for
homogenization and lipoprotein isolation.
Homogenization of all aortic tissues was performed in an
ice/water slush bath with a motorized homogenizer using 30-s
interval bursts five times, incorporating a 2-min rest between
homogenization cycles. Crude homogenates were centrifuged
at low speed at 15,000 g for 30 min at 0 °C, and the insoluble
pellet was discarded. This low speed supernatant (designated as
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lesion homogenate) was then used for sequential buoyant den-
sity isolation of LDL/VLDL (d	 1.063), HDL (d 1.063–1.21),
and lipoprotein-depleted (LPD) fractions (d 1.21). Ultracen-
trifugation fractions were recovered and then dialyzed at
0–4 °C four times against 4 liters of 5 mM ammonium bicar-
bonate with addition of antioxidants 50 M DTPA, pH 7.4 and
25 M butylated hydroxytoluene changed every 4 h. Finally,
buffer was changed against 4 liters of ice-cold Chelex-100-
treated 1 PBS, pH 7.4. Butylated hydroxytoluene was omitted
from the apoA-I preparations isolated for use in LCAT or cho-
lesterol efflux activity measurements. To further prevent artifi-
cial oxidation, all dialyses were performed in large glass air-
tight jars with argon-sparged buffer and an argon overlay to
purge headspace gases.
Immunoaffinity Isolation of ApoA-I from Aortic Tissue
Homogenate—Anti-NO2-Tyr166-apoA-I immunoaffinity resin
was prepared by covalently coupling mAb 4G11.2 to Amino-
Link Plus (Pierce) resin at an antibody density of 1.5 mg of
mAb/ml of resin in an amine-free buffer (PBS, pH 7.4) accord-
ing to the manufacturer’s instructions. Reactive non-antibody-
bound sites on the resin were blocked with addition of excess
ethanolamine. The affinity gel was then drained, and the anti-
body concentration in the flow-through fractions was deter-
mined. The resulting cross-linking efficiency was calculated to
be greater than 90%. The gel was then extensively rinsed with 1
M Tris, pH 7.4, 1 M NaCl and then equilibrated in 1 PBS, pH
7.4 prior to use or storage (0.002% sodium azide was added for
storage). Individual one-time use affinity columns (1 ml;
drained resin) were preparedwith immobilized 4G11.2, and the
artery wall apoA-I was purified from individual samples of aor-
tic homogenates using conditions that quantitatively recovered
apoA-I as confirmed using Western blot analyses of column
fractions. Total apoA-I was similarly immunoprecipitated
using immobilized mAb 10G1.5 similarly coupled to Amino-
Link Plus (Pierce) resin.
Immunochemistry Staining of Atherosclerotic Coronary
Arteries—Atherosclerotic coronary artery segments (fresh fro-
zen tissue blocks) were obtained from the explanted hearts of
patients undergoing cardiac transplantation at the Cleveland
Clinic. Fresh frozen tissue blocks from normal coronary arter-
ies were obtained from transplantation donor hearts that had
been removed but were subsequently not used. Immunohisto-
chemistry on atherosclerotic and normal coronary arteries was
performed using anti-human NO2-Tyr166-apoA-I antibody
4G11.2 or polyclonal rabbit anti-humanMPO (catalogue num-
berA0398, DakoNorthAmerica, Inc., Carpinteria, CA), each at
a dilution of 1:400. Mouse normal IgG1 (catalogue number
X0931, Dako North America, Inc.) was used as an isotype con-
trol for the antibody staining. The staining procedure followed
the protocol of the DakoCytomation Envision system HRP
(3-amino-9-ethylcarbazole) (Dako North America, Inc.).
Modification of ApoA-I byMPO-generated Reactive Nitrogen
Species—TheMPO-mediated modification reactions were car-
ried out in a 50mM sodiumphosphate buffer, pH 7.0 containing
100 M DTPA, 1 mg/ml protein (apoA-I), 57 nM purified
humanMPO (donor, hydrogen peroxide; myeloperoxidase, EC
1.11.2.2;A430/A280 ratio of 0.79), and 100MNaNO2.TheMPO
reactionswere initiated by adding hydrogen peroxide at varying
concentrations as indicated in Fig. 1 (typically 0–200 M as
needed) and carried out at 37 °C for 1 h. These reaction condi-
tions included physiologically relevant amounts of MPO, chlo-
ride, and nitrite and hydrogen peroxide concentrations that
ranged from physiologic to pathophysiological.
Mass Spectrometry Analyses—To confirm that the recombi-
nant apoA-I was nitrated only at position 166 and at complete
saturation, after SDS-PAGE, the major gel bands at molecular
mass 25 kDa were excised for wild-type apoA-I and for NO2-
Tyr166-apoA-I. Samples were first treated with dithiothreitol/
iodoacetamide (Sigma), and then proteins were digested using
mass spectrometry grade trypsin (Promega) at 37 °C overnight.
Tryptic peptides were loaded onto an IntegraFrit sample trap
(ProteoPep C18, 300 Å, 150 m  2.5 cm; New Objective,
WoburnMA) at 1 l/min with 5% acetonitrile and 0.1% formic
acid to desalt the samples. The peptides were subsequently
eluted through a column (75 m  15 cm) packed in-house
with XperTek 218TP (C18, 300-Å pore size, 150-m particle
size; Cobert Associates, St. Louis, MO) at 200 nl/min using a
Proxeon Easy-nLC II system (Thermo Scientific, Waltham,
MA) with a gradient of 5–65% acetonitrile, 0.1% formic acid
over 120 min into an OrbitrapVelos mass spectrometer
(Thermo Scientific).
Peak lists were generated using Proteome Discoverer 1.1
(Thermo Scientific, Waltham, MA). The resulting unified
search files (*.srf) were searched against the UniProt FASTA
database of all apolipoproteins and against a human protein
database downloaded from the European Bioinformatics Insti-
tute (release 2013_02). The amino acid modifications used for
searches included carbamidomethylated cysteine (fixed), oxi-
dized methionine and tryptophan (variable), and 3-chloro- and
3-nitrotyrosine (variable). Only strictly tryptic peptides with a
maximum of two missed cleavage sites were allowed in the
database searches. Monoisotopic precursor ions were searched
with a tolerance of 100 ppm with 0.8 Da for the fragment ions
on the data obtained from the hybrid LTQ-Orbitrapmass spec-
trometer. Unidentified fragment ions in all fragmentation spec-
tra were manually validated using Protein Prospector (University
of California, San Francisco). Incorporation of 3-nitrotyrosine
only at position 166 with complete saturation was confirmed.
Reconstituted HDL composition was analyzed as described
previously using microphosphate for phospholipid quantifica-
tion and stable isotope dilution liquid chromatography with
on-line liquid chromatography (LC) electrospray ionization
tandem mass spectrometry (MS/MS) analysis to quantify both
amino acid (Phe, Val, and Leu) and cholesterol content on an
API 5000 triple quadrupole mass spectrometer (AB SCIEX)
(12). Protein content was calculated assuming a protein
sequence of human apoA-I and demonstrated comparable
results using any of the three amino acids monitored. As a con-
trol, the content of cholate in reconstituted HDL particle prep-
arations was also quantified by LC/electrospray ionization/
MS/MS on the API 5000 instrument and confirmed to be	0.1
mol % (12).
Statistical Analysis—The statistical significance of differ-
ences was determined by Student’s t test or analysis of variance
where more than two comparisons were made. p values for
statistical significance are reported for p	 0.05.
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Monoclonal Antibody 4G11.2 Recognizes ApoA-I Selectively
Nitrated at Position 166—We first reported that apoA-I was a
preferential target of protein nitration within atherosclerotic
lesions, and in our later studies, NO2-Tyr166-apoA-I was iden-
tified as a preferred site of nitration using proteomics studies (7,
8). We initially sought to develop an mAb that specifically rec-
ognized this site-specific nitrated apoA-I to better study its
abundance and particle distribution. We further wished to use
thismAb as a tool to immunoaffinity purify and probe the func-
tion of in vivo apoA-I harboring this modification. As antigen,
purified delipidated human apoA-I (isolated fromplasmaHDL)
was nitrated in vitro using the complete MPO/H2O2/NO2 sys-
tem at a 5:1 molar ratio of oxidant to apoA-I (protein nitration
conditions) and injected into several apoA-I/ mice. After a
robust antibody response was generated, splenocytes from the
animalswere used to generate hybridomas.After screening sev-
eral thousand hybridoma clones for their ability to recognize
apoA-I exposed to the MPO/H2O2/NO2 system but not other
oxidized (non-nitrative) forms of apoA-I or native apoA-I, sev-
eral clones were identified.
At this stage, we next turned our attention to characterizing
these hybridoma clones to determinewhether any expressed an
antibody that selectively recognized apoA-I nitrated specifi-
cally at tyrosine 166. One mAb, named 4G11.2, was selected
based upon its specific activity of recognition by ELISA, immu-
noblot analysis, and finally, its ability to immunoprecipitate
NO2-Tyr166-apoA-I. Fig. 1, A and B, collectively demonstrate
the recognition selectivity of mAb 4G11.2 to detect only
nitrated apoA-I at position 166. In Fig. 1A, mAb 4G11.2 only
recognizes apoA-I exposed to the MPO/H2O2/NO2 system
(NO2-A1) but not unoxidized plasma-purified human apoA-I.
Our prior in vitro and in vivo proteomics studies with apoA-I
revealed that of the seven potential tyrosine residues only three
are nitrated to any significant degree, Tyr18, Tyr166, and Tyr192
(8). Selectivity for mAb 4G11.2 to recognize nitration at tyro-
sine 166 of apoA-I was then demonstrated by examining mAb
binding to synthetic peptides spanning Tyr18, Tyr166, or Tyr192
in either native form or with site-specific incorporation of a
nitrotyrosine at the indicated residue (see “Experimental Pro-
cedures” for peptide sequences). Of note, mAb 4G11.2 only
recognized the NO2-Tyr166-containing peptide but not the
non-nitrated version of the Tyr166-containing peptide or other
NO2-Tyr-containing peptides (e.g. NO2-Tyr18 and NO2-
Tyr192). Selectivity of mAb 4G11.2 was further demonstrated
by its lack of recognition of other possibly nitrated tyrosine
residues within apoA-I using the apoA-I Tyr166Phe mutant in
comparisonwithwild-type apoA-I after oxidationwith increas-
ing levels of oxidant with the MPO/H2O2/NO2 system (Fig.
1B). Although wild-type apoA-I was readily detected by 4G11.2
upon exposure to increasing levels of oxidant, apoA-I
Tyr166Phe mutant where only tyrosine 166 is mutated to the
relatively non-oxidizable (and non-nitratable) phenylalanine
was not (Fig. 1B).
The specificity of mAb 4G11.2 for recognition of either
apoA-I or rHDL only following exposure to nitrating oxidant
systems and not in native form or following exposure to alter-
native oxidant systems is shown in supplemental Fig. 1. ApoA-I
and rHDL were only recognized following exposure to the
MPO/H2O2/NO2 system, ONOO, or ONOO/HCO3 but
not following exposure to multiple alternative oxidation sys-
tems (as described under “Experimental Procedures”). Further
studies as outlined below showed that mAb 4G11.2 only recog-
nized protein bands within human plasma and tissue homoge-
nates on Western analyses at the molecular weight of the
apoA-I monomer and higher molecular weight forms consis-
tent with dimer, trimer, and higher cross-linked apoA-I forms.
Proteomics analyses of immunoaffinity-isolated recovered pro-
tein from these tissue matrices revealed apoA-I in each band.
Collectively, these results show that mAb 4G11.2 is highly spe-
cific for recognition of NO2-Tyr166-apoA-I. Moreover, impor-
tantly, 4G11.2 did not recognize either native apoA-I or apoA-I
following exposure to multiple alternative oxidative pathways.
FIGURE1.Amonoclonal antibody that recognizesapoA-I nitratedat tyro-
sine 166. A, specificity and epitope mapping of mAb 4G11.2 to nitrated
apoA-I was performed using ELISAs as described under “Experimental Proce-
dures.” The indicated protein (apoA-I or oxidized apoA-I forms) or indicated
peptides and nitrated peptides were coated onto enzyme immunoassay
plates at 10M in triplicate and incubatedwithmAb4G11.2, and ELISAs were
performed.B, 4G11.2 fails to recognize anyother oxidizedor nitrated residues
within apoA-I other than nitrated apoA-I containing an oxidizable tyrosine at
position 166. Wild-type or Y166F-mutated apoA-I were oxidized in vitrowith
increasingmolar ratios of oxidant as indicated and then coated onto enzyme
immunoassay plates, and ELISAs were performed as described in A. Values
represent the average of three reactions; error bars indicate S.D.
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NO2-Tyr166-apoA-I Is Abundant within Atherosclerotic
Lesions but Present as a Lipid-poor Form Rather than within
HDL-like Particles—As noted above, there is some controversy
over whetherNO2-Tyr166-apoA-I is present within human ath-
erosclerotic lesions and if so to what level. Therefore, we ini-
tially sought to use mAb 4G11.2 to determine whether NO2-
Tyr166-apoA-I was present within human lesions. Should this
be the case, this findingwould be an important preface to deter-
mining abundance, particle distribution, and function (if pres-
ent in high enough levels to be recoverable for biological activ-
ity assays) within the atherosclerotic artery wall and the normal
artery wall. Thus, immunohistochemical staining of human
coronary arteries was performed. Both atherosclerotic lesions
and normal human coronary artery tissue were examined.
NO2-Tyr166-apoA-I was readily observed throughout the ath-
erosclerotic plaque, but essentially no staining was evident in
normal human coronary artery tissue (Fig. 2, left). No staining
was observed with isotype control antibody, corroborating the
specificity of 4G11.2 staining (Fig. 2, right). Staining of parallel
sections with rabbit anti-human MPO polyclonal antibodies
also revealed an intense staining pattern in human atheroscle-
rotic plaque. Only mild MPO staining was observed in normal
human coronary arteries that was localized to the endothelial
surface and subendothelial space (Fig. 2,middle).
Wenext sought to examine both the particle distribution and
amount of NO2-Tyr166-apoA-I in human atherosclerotic
lesions. Human aortic plaque material recovered fresh at time
of surgery was obtained as outlined under “Experimental Pro-
cedures.” Tissues were rinsed free of bloodwith PBS and placed
in buffer containing antioxidant mixture, stored in gas-tight
containers after sparging with argon to remove air, sealed, and
stored at80 °C until time of isolation (see “Experimental Pro-
cedures”). Tissues frommultiple subjects were homogenized in
antioxidant buffer and centrifuged at low speed to remove gross
particulate material. This supernatant (called “homogenate”
henceforward) was then subjected to sequential buoyant den-
sity gradient ultracentrifugation using the D2O/sucrose
method (24) to avoid high salt concentrations present with typ-
ical KBr-dependent lipoprotein fractionation methods. Ini-
tially, VLDL/LDL-like fractions (d 	 1.063) were removed.
Then, theHDL-like fraction (d 1.063–1.21) and LPD fraction
(d  1.21) were recovered as described under “Experimental
Procedures.”
Homogenate,HDL-like particle, andLPD fractionswere sep-
arated by gradient (5–15%) reducing SDS-PAGE, stained for
protein with SYPRO Ruby Red, and imaged. Visual inspection
of the gel (Fig. 3A) reveals a complex proteinmixture withmin-
imal variation in sample to sample protein banding patterns. A
notable protein band migrating at 27 kDa is also observed,
consistent with the molecular mass of apoA-I (Fig. 3A). West-
ern blot analysis of amembrane containing transferred proteins
from a parallel-run duplicate gel was probed with anti-NO2-
Tyr166-apoA-I antibody (mAb 4G11.2). Of note, NO2-Tyr166-
apoA-I within the homogenate and LPD fractions migrating at
27 kDa, the size of an apoA-I monomer, along with much
lighter staining bands migrating at just over 50 and 75 kDa,
consistent with dimeric and trimeric apoA-I forms, were
observed (Fig. 3B, molecular masses of apoA-I monomer,
dimer, and trimer are marked by arrowheads). Remarkably, the
HDL-like particle fraction had very light to no detectable NO2-
Tyr166-apoA-I present. In fact, the blot had to be highly over-
exposed to observe the presence of this modified form of
apoA-I in the HDL-like fraction (Fig. 3B, bottom panel).
Quantification of NO2-Tyr166-apoA-I within human athero-
sclerotic lesions showed that a large preponderance of this
modified form of apoA-I within lesion tissues is in a lipid-poor
form and not in an HDL-like particle with the vast majority
recovered within the LPD fraction (Fig. 4A). Remarkably, NO2-
Tyr166-apoA-I accounted for 8% of the total apoA-I recov-
ered in human atherosclerotic plaque with this almost exclu-
sively being found in the LPD fraction (Fig. 4B). Further
quantitative analysis of NO2-Tyr166-apoA-I/total apoA-I found
within each fraction is shown in Fig. 4C.
Only Trace Levels of NO2-Tyr166-apoA-I Are Observed in
Plasma and as a Lipid-poor Form Not within an HDL Particle—
We next examined the distribution and level of NO2-Tyr166-
apoA-I within plasma from normal healthy consenting donors
(n 5). Plasma was fractionated by sequential buoyant density
ultracentrifugation. The starting plasma, HDL-rich fraction,
and lipoprotein-depleted fraction were then separated by gra-
dient (5–15%) reducing SDS-PAGE and either stained with
Coomassie Blue (Fig. 5A) or transferred to membranes and
probed with either anti-total apoA-I (mAb 10G1.5) (Fig. 5B) or
mAb 4G11.2 to visualize NO2-Tyr166-apoA-I (Fig. 5C). As
expected, amajor band staining at27 kDa in theHDL fraction
of the Coomassie Blue-stained gel was noted (Fig. 5A) that cor-
responds with immunoreactive bands observed after probing
with anti-total apoA-I (mAb 10G1.5) (Fig. 5B). For theWestern
analyses using mAb 10G1.5, which recognizes total apoA-I,
unequal (less) protein loading of the HDL fraction was neces-
sary compared with total protein used in the plasma and LPD
fractions to avoid grossly overloading apoA-I signal intensities
in the HDL fraction (Fig. 5B). Remarkably, as was observed in
the atherosclerotic lesion, NO2-Tyr166-apoA-I was detected
(withmAb 4G11.2) only in the startingmaterial (plasma) and in
the lipid-poor LPD fraction (Fig. 5C) but not within the HDL
fraction, despite readily apparent apoA-I within the HDL frac-
FIGURE 2. ApoA-I nitrated on tyrosine 166 is located in atherosclerosis-
laden human coronary artery. Fresh frozen sections of human coronary
aortic tissue segments with (top row; cardiovascular disease (CVD)) and with-
out (bottom row; Normal) atherosclerotic plaque were stained using either
mAb 4G11.2 (anti-NO2-Tyr
166-apoA-I), anti-MPO-specific antibody, or isotype
control IgG (Ab) asdescribedunder “Experimental Procedures.” Sectionswere
counterstained with hematoxylin (blue), and MPO-positive staining is red.
Magnification, 5; scale bar, 250 m.
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tion as visualized with the anti-total apoA-I mAb 10G1.5 (Fig.
5B). As can be seen, mAb 4G11.2 failed to recognize recombi-
nant unmodified apoA-I (Fig. 5C, control sample (C)), whereas
mAb 10G1.5 (anti-total apoA-I) easily recognized it (Fig. 5B).
Quantification of NO2-Tyr166-apoA-I in plasma within both
the HDL and LPD fractions is shown in Fig. 6. Of note, NO2-
Tyr166-apoA-I in plasma was only present at 0.14% of total
apoA-I. Moreover, even following long overexposure of the
blot, immunoreactive bands were not detected in theHDL-rich
fraction. Similarly, FPLC fractionation of plasma and subse-
quent Western blot analyses confirmed no immunodetectable
monomeric NO2-Tyr166-apoA-I within fractions where HDL
particles elute and detection of themodified protein with lower
molecular weight lipid-poor forms of apoA-I (data not shown).
Thus, we were not able to detect any NO2-Tyr166-apoA-I in the
HDL fraction with all of the NO2-Tyr166-apoA-I partitioned
into the LPD fraction (d 1.21) as a lipid-poor form.
NO2-Tyr166-apoA-I Is Nearly 100-fold Enriched in Lesions
Relative to Normal Aortic Tissue and Is Not Found on an HDL-
like Particle in Normal Aortic Tissues—Given the stark differ-
ence in abundance of NO2-Tyr166-apoA-I observed in the ath-
erosclerotic artery wall versus that found in plasma (i.e. one in
FIGURE 3. ApoA-I nitrated on tyrosine 166 present in human atheroscle-
rotic lesions is not located on HDL-like particles. Proteins in atheroscle-
rotic lesion homogenate or after sequential D2O/sucrose buoyant density
ultracentrifugation fractionation into HDL-like particle and lipoprotein-de-
pleted fractions from the indicated density ranges were separated by gradi-
ent (5–15%) reducing SDS-PAGE. A, SYPRO Ruby-stained gel of the indicated
protein samples (5 g) from homogenate and the indicated density ranges
obtained fromdifferentatherosclerotic lesion tissue samples (n5).B, toppanel,
Western blot membrane of a duplicate-run gel as in A probed with anti-NO2-
Tyr166-apoA-I mAb 4G11.2. B, bottom panel, overexposure of Western blot to
showNO2-Tyr
166-apoA-I in theHDL-like fraction.Monomers, dimers, and trimers
(multimers)ofapoA-I-immunoreactiveNO2-Tyr
166-apoA-Ibandsare indicatedby
arrowheads. Molecularmassmarkers are indicated.
FIGURE 4. Quantitation of nitrated NO2-Tyr
166-apoA-I present in human
atherosclerotic lesions. A, recovery of apoA-I (g) per gram of lesion tissue
(wet weight) from the atherosclerotic lesion tissue homogenate and in the
HDL-like and LPD fractions was calculated from quantitative Western blot
analysisof apoA-I-immunoreactivebands,andtotalapoA-Icontentasdescribed
under “Experimental Procedures” is qualitativelypresented inB.B, percentageof
NO2-Tyr
166-apoA-I to total apoA-I fromatherosclerotic lesionpresent in the start-
ing homogenate and HDL-like and LPD fractions was calculated as in A. C, per-
centage of NO2-Tyr
166-apoA-I to total apoA-I within each fraction was deter-
mined by quantitative Western blot analysis of apoA-I-immunoreactive bands.
Valueswere determined from n 5 samples; error bars representS.D.
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12 apoA-I molecules in the atherosclerotic artery wall versus
one in 750 apoA-I molecules in plasma is nitrated on tyrosine
166), wewanted to examinewhetherNO2-Tyr166-apoA-I could
be detected in the normal artery wall. Furthermore, we wanted
to determine its abundance and particle distribution. Normal
human aortic tissue (from n 5 subjects) was obtained at time
of organ harvest from transplant donors, and homogenates
were prepared and fractionated by sequential D2O/sucrose
buoyant density ultracentrifugation as described under “Exper-
imental Procedures.” Direct comparison of normal versus
lesion aortic homogenates by 5–15% reducing SDS-PAGE fol-
lowing protein staining (Fig. 7A) and following Western blot
analysis from parallel-run gels probed with mAb 4G11.2 (Fig.
7B) showed that there was significantly less (nearly 100-fold)
immunoreactive apoA-I in normal artery homogenates than in
those from atherosclerotic lesions (Fig. 7, C and D).
FIGURE5.ApoA-Initratedontyrosine166present inplasma isnotonHDL
particles, is lipid-poor, and is only found in the lipoprotein-depleted
fraction.Plasma fromnormal healthy humanvolunteers (n 5)was fraction-
ated by sequential D2O/sucrose buoyant density gradient centrifugation. A,
Coomassie Blue-stained gel after gradient (5–15%) SDS-PAGE of the plasma,
HDL, and LPD fraction proteins (10 g of protein/lane). B, Western blot anal-
ysis of proteins on a membrane transferred from a duplicate fractionated
protein gel in A with 10 g of protein loaded per lane from the plasma and
LPD fractions and 0.8 g in the HDL fractions (not to overload the immuno-
reactive signal) probed with anti-total apoA-I mAb 10G1.5 shows that apoA-I
is predominately in theHDL fraction. Recombinant apoA-I (0.8g) served as a
positive control (C). C, Western blot analysis of the same amounts of proteins
on membrane from a duplicate fractionated protein gel as in A probed with
anti-NO2-Tyr
166-apoA-I mAb 4G11.2 shows that apoA-I is not present in the
HDL fraction but is present only in the lipid-poor LPD fraction (d  1.21
mg/ml) and that mAb 4G11.2 does not recognize non-nitrated apoA-I (C; 0.8
g). Values were determined from (n 5 samples. Overexposure of C reveals
that there is no NO2-Tyr
166-apoA in plasma HDL fractions (not shown).
FIGURE 6. Quantitation of apoA-I nitrated on tyrosine 166 present in
plasma.A, recovery ofNO2-Tyr
166-apoA-I (g) perml of plasmapresent in the
starting plasma and in the HDL-like and LPD fractions after sequential D2O/
sucrose buoyant density gradient ultracentrifugation was determined from
quantitativeWesternblot analysis of apoA-I-immunoreactivebands and total
apoA-I content as described under “Experimental Procedures” and is qualita-
tively presented in B andC. B, percentage ofNO2-Tyr
166-apoA-I to total apoA-I
from plasma present in the starting material and HDL-like and LPD fractions
was calculated from quantitative Western blot analysis of apoA-I-immunore-
active bands as inA.C, percentage ofNO2-Tyr
166-apoA-I to total apoA-Iwithin
each fraction was determined by quantitativeWestern blot analysis of apoA-
I-immunoreactive bands. Values were determined from n 5 samples; error
bars representS.D. N.D., not able to be detected.
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We next examined the particle distribution of NO2-Tyr166-
apoA-I recovered from normal human artery wall. Western
blot analyses with anti-total apoA-I (mAb 10G1.5) demon-
strated low but detectable levels of apoA-I inHDL-like particles
recovered from normal human aorta (Fig. 8A). Although
apoA-I is present on the blot in relatively equal abundance, the
amount of protein required to generate an equivalent immuno-
reactive signal was nearly 20% of the entire HDL-like fraction
protein material, whereas the amount of protein loaded in the
homogenate or the LPD fraction was only 0.2% of the total
protein present in those fractions. Identically prepared mem-
branes from SDS-PAGE probed instead with anti-NO2-Tyr166-
apoA-I antibody (mAb 4G11.2) revealed no detectable bands
within the HDL-like fraction, and all immunoreactive species
within the LPD fraction (Fig. 8B). Interestingly, the immunore-
active bands migrated not only at 27 kDa, the size of an
apoA-I monomer, but also at higher molecular weights as well
(corresponding to molecular weights of the apoA-I dimer,
trimer, etc.), consistent with appreciable oxidative cross-link-
ing present in this material (Fig. 8B). Quantification of NO2-
Tyr166-apoA-I in homogenate and LPD fractions from normal
aortic tissues showed that there is only 1 g of NO2-Tyr166-
apoA-I/g wet weight of aortic tissue (Fig. 8C), accounting for
only 0.12–0.14% of total apoA-I within artery wall homoge-
nate and the LPD fraction (Fig. 8D).
ApoA-I Harboring Site-specific 3-Nitrotyrosine at Position
166 in Vivo Is Functionally Impaired—We did not have access
to sufficient quantities of human aortic tissue to recover
enough pure NO2-Tyr166-apoA-I for biological characteriza-
tion. Therefore, to interrogate the functional properties of
apoA-I containing a nitrotyrosine at position 166 formed in
vivo, we collected units of plasma from 11 different healthy
volunteers and immunopurified NO2-Tyr166-apoA-I as
described under “Experimental Procedures.” In parallel, bulk
total apoA-I was affinity-purified from the same plasma sam-
ples using an anti-total apoA-I antibody. Recovery of the NO2-
Tyr166-apoA-I and total apoA-I by their respective immunoaf-
finity resins was quantitative under the conditions used as
assessed byWestern blot analyses (data not shown). BothNO2-
Tyr166-apoA-I and total apoA-I from the individual samples
were delipidated, then reconstituted by a cholate dialysis
method into rHDL, and further purified by polishing analytical
gel filtration FPLC as described under “Experimental Proce-
dures.” Then comparable amounts (1 g of apoA-I mass) of
rHDL formed from each subject’s NO2-Tyr166-apoA-I versus
total apoA-I were examined for LCAT activity as described
under “Experimental Procedures.” Remarkably, rHDLs formed
using immunoaffinity-isolatedNO2-Tyr166-apoA-I were highly
defective in their ability to stimulate LCAT activity, collectively
showing a 88.1  8.5% reduction in activity (p 	 0.001 com-
pared with rHDLs prepared from total apoA-I; Fig. 9). These
results for the first time directly demonstrate that apoA-I har-
boring a nitrotyrosine at 166 in vivo has impaired LCAT-acti-
vating function. They also demonstrate that the apoA-I
detected by 4G11.2 in plasma is “dysfunctional.”
FIGURE 7.ApoA-I nitrated on tyrosine 166 obtained from the normal aortic
tissue is not on an HDL-like particle and behaves similarly to that isolated
from atherosclerotic lesions. Aortic tissue that was histopathologically deter-
mined to appear normalwas used to prepare a tissue homogenate as described
under “ExperimentalProcedures.”A, aortic tissuehomogenates fromnormaland
atherosclerotichumanarterywall tissue (n5each)with the indicatedamounts
of protein were fractionated by gradient (5–15%) SDS-PAGE and stained with
SYPRO Ruby Red. B, Western blot of duplicate gel as in A with the indicated
amount of protein (15 g) per lane (n 5) probed with anti-NO2-Tyr
166-apoA-I
mAb 4G11.2.C, recovery of apoA-I (g) per gramof tissue (wetweight) from the
normal aortic tissue and fromatherosclerotic lesion tissuewas determined from
quantitative Western blot analysis of apoA-I-immunoreactive bands and total
apoA-I content as described under “Experimental Procedures” and is qualita-
tively presented in Figs. 8B and 4B. D, percentage of NO2-Tyr
166-apoA-I to total
apoA-I present in the startingmaterial as indicatedwasquantified as inC. Values
were determined from n 5 samples; error bars representS.D.
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166-apoA-I immunopurified frombiological material
usingmAb 4G11.2 is dysfunctional for LCAT activity. LCAT activity was
measured in NO2-Tyr
166-apoA-I immunoaffinity-purified from normal
healthy human plasma (n  11 different subjects) and reconstituted into
rHDL particles as described under “Experimental Procedures.” ApoA-I iso-
lated from plasma HDL recovered from these same healthy donors (n 
11) using an anti-total apoA-I chicken IgY antibody (Sigma) and rHDL
formed from these apoA-Is served as individual internal controls for
LCAT activity. Bars represent triplicate determinations; error bars repre-
sentS.D. Percent inhibition was calculated, and p values less than 0.001
were significant.
FIGURE 10. Strategy for incorporation of a nitrotyrosine into a protein
of interest using an orthogonal tRNAUAG/nitro-Tyr-tRNA synthetase.
The schematic depicts how the orthogonal incorporation of 3-nitroty-
rosine site-specifically at amber codons (TAG) into proteins occurs. The
tyrosyl-tRNA synthetase fromM. jannaschii is mutated at a number of sites
based upon structural information, and a library of these mutant tRNA
synthetases is screened for their ability to incorporate the 3-nitrotyrosine
but not any other natural amino acid. The selected mutated nitro-Tyr-
tRNA synthetase then charges the orthogonal tRNACUA with nitrotyrosine,
which is then translationally incorporated into the protein of interest site-
specifically with high fidelity at the TAG codon. aaRS, aminoacyl-tRNA
synthetase.
FIGURE 8.ApoA-I nitrated on tyrosine 166 obtained from the normal aortic
tissue is not on anHDL-like particle.A, aortic tissue that appears histologically
normal was used to prepare a tissue homogenate as described under “Experi-
mental Procedures.” The homogenate was fractionated on sequential D2O/su-
crosebuoyantdensitygradientsbyultracentrifugation, the indicatedamountsof
protein were separated by gradient (5–15%) reducing SDS-PAGE, and proteins
were transferred to membranes. A, Western blot of normal artery wall proteins
(15g) fromhomogenate andHDL-like andLPD fractionsprobedwithanti-total
apoA-I antibodymAb10G1.5 todetect total apoA-I inhomogenateandHDL-like




and in theLPD fraction.C, recoveryofNO2-Tyr
166-apoA-I (g)pergramofnormal
aortic tissue (wet weight) that was found to be present in the homogenate
(Homog.) and in the HDL-like and LPD fractions was determined from quantita-
tiveWesternblotanalysisofapoA-I-immunoreactivebandsandtotal apoA-I con-
tentasdescribedunder“ExperimentalProcedures”andisqualitativelypresented
in Fig. 9. D, percentage of NO2-Tyr
166-apoA-I to total apoA-I from normal aortic
tissue present in the starting homogenate and HDL-like and LPD fractions was
calculated from quantitative Western blot analysis of apoA-I-immunoreactive
bands as calculated in C. Valueswere determined from n 5 samples; error bars
representS.D.
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Functional Interrogation of Site-specific 3-Nitrotyrosine
Incorporated into ApoA-I Using an Evolved Orthogonal tRNA
Synthetase—Although the above immunopurification studies
with mAb 4G11.2 are consistent with results observed with in
vitro exposure of rHDL to MPO-generated oxidants (8), it is
impossible to determine what the exact contribution of tyro-
sine 166 nitration in apoA-I alone is toward LCAT activity or
other functional assays such as cholesterol efflux because the
immunoaffinity-isolated NO2-Tyr166-apoA-I material has many
other confounding sites of oxidative modification. To specifi-
cally address this problem, we produced wild-type and mutant
apoA-I protein that contained 3-nitrotyrosine regiospecifically
incorporated only at position 166 through engineering an
orthogonal tRNATyr/tyrosyl-tRNA synthetase originally from
M. jannaschii (35). By evolving this system to exclusively use
nitrotyrosine and not tyrosine (pDULE 5B) and then using it for
recombinant expression from an apoA-I amber codon-inter-
rupted gene, we were able to site-specifically insert exclusively
3-nitrotyrosine withMj-nitro-Tyr-tRNA synthetase/tRNACUA
(16). A schematic illustrating the system for incorporating this
unnatural amino acid into a protein at a specific site(s) of inter-
est is presented in Fig. 10.
We prepared an E. coli codon-optimizedHis8-tagged human
apoA-I allele and an Amber166 mutant version of this allele
(Y166TAG-apoA-I) for recombinant protein expression (see
“Experimental Procedures” for details). Both wild-type and
mutant apoA-I alleles were transformed into bacteria harbor-
ing the evolved orthogonal Mj-nitro-Tyr-tRNA synthetase/
tRNACUA, and expression was induced in minimal medium
with supplements either lacking (for the wild-type apoA-I) or
supplemented with 1 mM free 3-nitrotyrosine (Y166TAG-
apoA-I mutant). Recombinant wild-type and mutant proteins
were purified as described under “Experimental Procedures,”
and equivalent amounts of each protein were fractionated by
gradient (5–15%) reducing SDS-PAGE and stained with Coo-
massie Blue. The stained gel revealed that the 3-nitrotyrosine-
containing protein was purified to the same degree and
migrated equivalently to the wild-type His8-apoA-I (Fig. 11A).
We then used NO2-Tyr166-apoA-I to reaffirm the specificity
and high affinity of mAb 4G11.2 (note that we did not have this
site-specific apoA-I form when first generating or characteriz-
ing mAb 4G11.2). Western analyses with mAb 4G11.2 failed to
recognize recombinant wild-type apoA-I (1.5 g) but readily
recognized the site-specifically nitrated apoA-I even at 1000-
fold lower levels of protein (e.g. 1.5 ng) (Fig. 11B). Visual inspec-
tion of the purified proteins showed that only the mutant pro-
tein is yellow in appearance, consistent with the incorporation
of 3-nitrotyrosine (see Fig. 11C, inset). Spectroscopic analysis of
the isolated recombinant NO2-Tyr166-apoA-I confirmed the
presence of the anticipated visible spectral absorbency maxi-
mumpeak at 428 nm (Fig. 11C).Moreover, proteomics analyses
of the mutant apoA-I protein revealed that 3-nitrotyrosine was
indeed incorporated at position 166 (supplemental Fig. 2, A and
B). Furthermore, 3-nitrotyrosine is site-specifically incorpo-
rated at site 166 with a fidelity that matches that of the natural
amino acid incorporation, showing amass increase of 45.17m/z
on all b and y ions present after the tyrosine in the nitrotyrosine
166 peptide spectra compared with those same b and y ions in
FIGURE11.Site-specific incorporationofanitrotyrosine intoposition166of
apoA-I. 3-Nitrotyrosine was site-specifically incorporated into human apoA-I at
position 166 in place of tyrosine using an evolved orthogonalMj-tRNAUAG/nitro-
Tyr-tRNA synthetase (16). A, purified WT and NO2-Tyr
166-apoA-I proteins (5 g
each)were fractionatedby gradient (5–15%) SDS-PAGE, and the gelwas stained
withCoomassieBlue.B,WTapoA-Iprotein (1.5g)with the indicatedamountsof
NO2-Tyr
166-apoA-I proteins was fractionated by SDS-PAGE, and the proteins
were transferred to membrane and probed with anti-NO2-Tyr
166-apoA-I mAb
4G11.2 to demonstrate that 4G11.2 fails to recognize non-nitrated apoA-I but
does specifically recognize NO2-Tyr
166-apoA-I. C, scanning wavelength spectro-
photometric absorbance profile for both wild-type and NO2-Tyr
166-apoA-I pro-
teins shows that only NO2-Tyr
166-apoA-I protein absorbs at 428 nm, the absorb-
ancemaximum for nitrotyrosine. The inset shows the yellow tinge in color of the
recombinantapoA-I that indicates incorporationof3-nitrotyrosine; thewild-type
apoA-I is colorless. D, native PAGE analyses of lipid-poor WT and NO2-Tyr
166-
apoA-IproteinsandreconstitutedHDLparticlespreparedfromeachasdescribed
under “Experimental Procedures.” Size standards are indicated in nm. Particle
compositions were determined as described under “Experimental Procedures”
and are listed below the gel as 1-palmitoyl-2-oleoylphosphatidylcholine (POPC):
cholesterol (Chol):apoA-I (mol:mol:mol).
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wild type apoA-I (supplemental Fig. 2A). This verification of
our ability to site-specifically incorporate 3-nitrotyrosine
within apoA-I confidently allowed us to probe the functional
consequences of nitration of only tyrosine 166 in apoA-I. Addi-
tionally, the NO2-Tyr166-His8-apoA-I protein also served as an
internal calibrator in quantifying NO2-Tyr166-apoA-I and total
apoA-I when using mAb 4G11.2 and anti-total apoA-I
antibodies.
In initial studies, we incorporated either wild-type apoA-I or
NO2-Tyr166-apoA-I into reconstituted HDL particles and
examined the particle preparations for both size distribution
and composition. Of note, both reconstituted HDL particle
preparationsweremonodispersed and demonstrated compara-
ble particle size (9.6 nm) (Fig. 11D). Compositional analyses
of theHDL preparations also demonstrated comparable results
for the HDL formed using either wild type or NO2-Tyr166-
apoA-I (Fig. 11D). Thus, apoA-I site-specifically nitrated only
at tyrosine 166 can generate in vitro reconstituted HDL parti-
cles that appear similar in terms of size and lipid composition to
those formed by wild type apoA-I.
Thus, we first evaluated the functional effect of selective
tyrosine 166 nitration of apoA-I onABCA1-specific cholesterol
acceptor function. Recombinantwild-type apoA-Iwas used as a
control for comparison with recombinant NO2-Tyr166-apoA-I
mutant protein. Increasing concentrations of each proteinwere
examined in cholesterol efflux assays using cholesterol-loaded
RAW264.7 macrophage cells in the absence and presence of
8-Br-cAMP pretreatment to induce ABCA1 expression, and
ABCA1-specific cholesterol efflux activity was quantified. As
observed, both the wild-type and mutant apoA-I proteins pro-
moted comparable levels of ABCA1-dependent cholesterol
efflux over a range of protein concentrations (Fig. 12A). We
next examined reconstituted nascent HDL particles prepared
from either wild-type apoA-I or NO2-Tyr166-apoA-I. Compa-
rable amounts (5 g of apoA-I mass) of each rHDL were incu-
bated with increasing amounts of human LCAT as indicated,
and LCAT activity was determined. Importantly, site-specific
nitration of only tyrosine 166 in apoA-I was shown to reduce
LCAT activity by 58.1  5.5% across multiple LCAT concen-
trations (Fig. 12B). Further kinetic analyses of LCAT activity in
rHDL formed by wild type versus NO2-Tyr166-apoA-I showed
reduction in both apparentKm andVmax for LCAT activity (Fig.
12C). The overall reduction in catalytic efficiency (Vmax/Km) for
NO2-Tyr166-apoA-I was45%. Collectively, these results show
that site-specific incorporation of 3-nitrotyrosine into apoA-I
at only position 166, a solvent-exposed residue and region com-
prising the solar flare we previously identified as interacting
with LCAT (12), results in significant selective impairment in
apoA-I LCAT activity with no effect on ABCA1-specific cho-
lesterol acceptor function.
DISCUSSION
Althoughmultiple investigators have affirmed that apoA-I is
a selective target for oxidative modification within the artery
FIGURE12.Site-specific incorporationofanitrotyrosine intoposition166
of apoA-I is dysfunctional for LCAT activity when reconstituted into an




dysfunctional as an ABCA1 cholesterol acceptor. ABCA1-dependent choles-
terol efflux activity of purified recombinant wild-type apoA-I and NO2-Tyr
166-
apoA-I proteinswasexamined in cholesterol-loadedRAW264.7macrophages
incubatedwith increasing levels of apoA-I protein (wild type and NO2-Tyr
166-
apoA-I) as indicated. Unfilled bars represent apoA-I wild-type protein; filled
bars represent NO2-Tyr
166-apoA-I. ABCA1-dependent cholesterol efflux
assays were performed as described under “Experimental Procedures.” B,
purified wild-type and NO2-Tyr
166-apoA-I proteins were used in LCAT activity
assays with increasing LCAT added as indicated (see “Experimental Proce-
dures” for details) to examine whether NO2-Tyr
166-apoA-I was dysfunctional
for LCAT activity. Percent inhibition and p values shown are averages across
the different concentrations examined. p values that were significant (less
than 0.001) and are indicated by an asterisk. C, double reciprocal plots (Lin-
eweaver-Burk plots) of wild-type and NO2-Tyr
166-apoA-I proteins used in
LCAT activity assays to determine Km, Vmax, and catalytic efficiency (Cat. Eff.)
(calculatedvalues are listed in the inset). Values represent theaverageof three
reactions; error bars indicate S.D. Diff, difference.
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wall (6–9, 13, 18, 19) and in vitro studies corroborate the func-
tional impairment of activity of the lipoprotein following oxi-
dation (7, 8, 12, 13, 19, 21), a debate exists as to relative abun-
dance of different site-specific oxidative modifications in vivo
and hence their potential functional and biological importance.
In this regard, nitration of tyrosine 166 stands out as a prime
example in this debate. Following immunoprecipitation of total
apoA-I from homogenates prepared from the atherosclerotic
artery wall, it was reported that NO2-Tyr166 modification of
apoA-Iwas an abundant PTM in vivo through proteomics stud-
ies (8). In contrast, in studies that followed using buoyant den-
sity centrifugation to isolate HDL-like particles, it was con-
cluded that nitration of tyrosine at this site on apoA-I is an
exceedingly low abundance product and therefore presumably
of little physiologically relevance (22). The present studies
unambiguously showed that nitration of apoA-I at tyrosine 166
is an exceptionally abundant modification in apoA-I in the dis-
eased artery wall where1 of every 12 apoA-Imolecules recov-
ered harbors this PTM. Furthermore, the present studies
showed that apoA-I that harbored this PTM, whether in the
human atherosclerotic lesion or the circulation, exhibited
marked impairment in function as monitored through loss of
LCAT activity. Finally, through use of orthogonal amino acid
substitution and incorporation of 3-nitrotyrosine site-specifi-
cally at only position 166 of apoA-I, a methodology used for the
first time in apoA-I, we were able to directly demonstrate that
the simple addition of the NO2moiety at the meta-position of
tyrosine 166 of apoA-I results in generation of a “dysfunctional”
protein. ApoA-I nitrated at tyrosine 166, a position previously
predicted to be highly solvent-exposed (located in the solar
flare domain) and a putative docking site for LCAT interaction
(12), is thus affirmed as an abundant dysfunctional form of
apoA-I in the atherosclerotic disease-laden artery wall. In fact,
NO2-Tyr166-apoA-I appears to be one of the more abundant
modified forms of apoA-I recovered from human atheroscle-
rotic plaque.
The reasons for the discrepant results obtained with respect
to this site-specific modification are also elaborated with the
present studies. Our work suggests that studies of buoyant den-
sity-isolatedHDL-like particles would not detect thismodifica-
tion as it is primarily associated with lipid-poor forms of
apoA-I. Interestingly, this distribution of NO2-Tyr166-apoA-I
was observed within both atherosclerotic lesions and the
plasma compartment.
There is much interest in understanding the functional role
of apoA-I modifications in vivo. The present studies highlight
that dramatic differences can be observed whether one uses
ultracentrifugation or uses more quantitative apoA-I recovery
approaches through the use of a high affinity antibody(s). In
these studies, an mAb that is highly selective and specific for
nitration of tyrosine 166 in apoA-I exclusively and not for other
sites of nitration within the protein or other nitrated proteins
was developed and used for quantification.
The role of nitrative and oxidative processes in contributing
to the inflammatory milieu within the artery wall has grown in
appreciation, as has the involvement of inflammatory processes
in the pathogenesis of cardiovascular disease (10, 36–42). The
present study reaffirms the concept thatMPO and nitric oxide-
derived oxidants are abundantly formed within the diseased
artery wall and suggests that detection and quantification of
circulating levels of this site-specific oxidized form of apoA-I
may serve as a barometer for monitoring a potential patho-
physiological process occurring in the artery wall. Further
studies are needed to evaluate the potential clinical utility of
quantifying circulating levels of this specific modified
apoA-I form as it relates to cardiovascular disease risks and
therapeutic responses.
Because epidemiological studies have long shown an inverse
association between circulating HDL-cholesterol (HDLc) or
apoA-I levels and both the prevalence of coronary artery dis-
ease and its major adverse events (43), a number of strategies
have recently been tried as a means of raising HDLc levels for
potential therapeutic benefit (43–48). Unfortunately, recent
clinical trials targeting raising HDLc levels have met with fail-
ure, calling into question the notion of elevating HDLc levels as
a means of promoting cardioprotective effects (43, 46–48).
One possible explanation for the failures may be that HDLc is
simply a “marker” and does not faithfully reflect a process in the
disease pathogenesis pathway. Indeed, there is an overwhelm-
ing body of evidence using animal models indicating that
apoA-I is atheroprotective (44, 45, 49–51). Recent evidence
supporting an atheroprotective effect of “functional” as
opposed to MPO-modified and dysfunctional apoA-I in vivo
has been reported (52). When either native (unoxidized)
apoA-I or MPO-oxidized apoA-I was injected subcutaneously
into apoE/ atherosclerosis-ladenmice under conditions that
showed comparable levels of apoA-I in the plasma compart-
ment, cholesterol efflux, reverse cholesterol transport, athero-
sclerotic plaque regression, and favorable phenotypic changes
in arterial tissue macrophages were only observed with native
apoA-I but not MPO-oxidized apoA-I (52). Additional evi-
dence for the atheroprotection that increased levels of apoA-I
or functional HDL particles can provide is found in human
clinical studies of either direct infusion of apoA-I, HDL, or
extracorporeal delipidated forms of apoA-I (53–56). The con-
flicting clinical trial results related to HDLc and/or apoA-I lev-
els thus emphasize the complexity and incomplete knowledge
of the relationship between circulating levels of HDL forms and
coronary artery disease pathogenesis (57). The present study
suggests that not only might it be the functionality of the HDL
particle or apoA-I rather than HDLc mass that may be more
important but that development of tools that can help probe the
relevant biology of apoA-I that is occurring within the artery
wall is also going to be of considerable value. Fully one in every
12 apoA-I molecules in the atherosclerotic artery wall contains
site-specific nitration at position 166, whereas only1 in 750–
1000 apoA-I molecules in the circulation harbors this modifi-
cation. These results further underscore that what is occurring
in the artery wall is quite distinct fromwhat is happening in the
plasma compartment. Consistent with this notion, recent stud-
ies using a monoclonal antibody specifically developed to rec-
ognize all forms of apoA-I equally well (lipidated and non-lipi-
dated forms as either native or various oxidized forms alike)
have shown that the function and distribution of apoA-I in the
artery wall are markedly distinct from those in plasma (58).
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In recent studies, the discovery of an alternative abundant
modified form of apoA-I in human atheroma was reported
usingmAb developed to specifically recognize apoA-Imodified
by theMPO/H2O2/Cl system (59). A 2-oxindolyl alaninemoi-
ety at Trp72 of apoA-I (oxTrp72-apoA-I) was shown to be spe-
cifically generated by MPO-catalyzed oxidation and to repre-
sent 20% of the apoA-I present in plaque, nearly twice the
abundance of NO2-Tyr166-apoA-I. Like NO2-Tyr166-apoA-I,
oxTrp72-apoA-I exists predominantly as a lipid-poor form and
is not recovered in the HDL fraction (59). Interestingly,
oxTrp72-apoA-I immunoaffinity purified from either human
atherosclerotic aortic tissues or plasma was shown to lack
ABCA1-dependent cholesterol efflux activity and in vivo HDL
biogenesis activity when injected into apoA-I knock-out mice
as well as to promote proinflammatory NF-B-activating activ-
ity (59).
Recent studies reveal that apoA-I within human atheroscle-
rotic plaque is 100-fold enriched compared with normal artery
wall, predominantly lipid-poor, not associated with HDL,
extensively oxidatively cross-linked, and functionally impaired
with respect to both cholesterol efflux and LCAT activities (58).
The present studies extend these observations by looking at a
specific oxidized form of apoA-I that is abundant within the
atherosclerotic plaque-laden artery wall. Taken together, the
present results and recent findings (52, 59) suggest that addi-
tional tools need to be developed to identify trace levels of
structurally distinct, functionally impaired modified forms of
apoA-I in the circulation that like NO2-Tyr166-apoA-I are
abundant in the diseased artery wall. Potential clinical utility of
monitoring such modified apoA-I forms was recently demon-
strated for oxTrp72-apoA-I in the circulation where elevated
levels among stable subjects presenting to an outpatient cardi-
ology clinic were associated with increased cardiovascular dis-
ease risk (59). Development of mAbs to distinct dysfunctional
apoA-I forms may prove to be a valuable tool in the future as a
means of monitoring distinct pathophysiological processes in a
diseased artery wall and formonitoring antiatherosclerotic bio-
logical activities of HDL-targeting therapies.
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